{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:22:56Z","timestamp":1771572176325,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurgie"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00104-022-01660-5","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T11:22:39Z","timestamp":1655119359000},"page":"644-651","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cholangiokarzinome\u00a0\u2013 intrahepatisches bis hil\u00e4res Gallengangkarzinom","Cholangiocarcinoma\u2014Intrahepatic to hilar bile duct cancer"],"prefix":"10.1007","volume":"93","author":[{"given":"Sebastian","family":"Rademacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timm","family":"Denecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Seehofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"1660_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.suronc.2020.06.004","volume":"34","author":"AC Sheka","year":"2020","unstructured":"Sheka\u00a0AC, Altman\u00a0A, Marmor\u00a0S et al (2020) Failure to administer multimodality therapy leads to sub-optimal outcomes for patients with node-positive biliary tract cancers in the United States. Surg Oncol 34:298\u2013303","journal-title":"Surg Oncol"},{"key":"1660_CR2","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.3390\/jcm10163559","volume":"10","author":"H Lang","year":"2021","unstructured":"Lang\u00a0H, Baumgart\u00a0J, Heinrich\u00a0S et al (2021) Liver resection for Intrahepatic cholangiocarcinoma-single-center experience with 286 patients undergoing surgical exploration over a\u00a0thirteen year period. J\u00a0Clin Med 10:3559","journal-title":"J Clin Med"},{"key":"1660_CR3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/jamasurg.2020.1973","volume":"155","author":"DI Tsilimigras","year":"2020","unstructured":"Tsilimigras\u00a0DI, Sahara\u00a0K, Wu\u00a0L et\u00a0al (2020) Very early recurrence after liver resection for Intrahepatic cholangiocarcinoma: considering alternative treatment approaches. JAMA Surg 155:823\u2013831","journal-title":"JAMA Surg"},{"key":"1660_CR4","doi-asserted-by":"publisher","first-page":"6725","DOI":"10.1245\/s10434-020-09536-w","volume":"28","author":"MC Mason","year":"2021","unstructured":"Mason\u00a0MC, Massarweh\u00a0NN, Tzeng\u00a0CD et\u00a0al (2021) Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? Implications from the neoadjuvant experience. Ann Surg Oncol 28:6725\u20136735","journal-title":"Ann Surg Oncol"},{"key":"1660_CR5","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1055\/a-1589-7854","volume":"60","author":"M Bitzer","year":"2022","unstructured":"Bitzer\u00a0M, Voesch\u00a0S, Albert\u00a0J et al (2022) S3-Leitlinie \u2013 Diagnostik und Therapie bili\u00e4rer Karzinome. Z\u00a0Gastroenterol 60:e186\u2013e227","journal-title":"Z Gastroenterol"},{"key":"1660_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1245\/s10434-012-2312-8","volume":"20","author":"A Kato","year":"2013","unstructured":"Kato\u00a0A, Shimizu\u00a0H, Ohtsuka\u00a0M et al (2013) Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a\u00a0retrospective single-center study. Ann Surg Oncol 20:318\u2013324","journal-title":"Ann Surg Oncol"},{"key":"1660_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/bjs.10641","volume":"105","author":"B Le Roy","year":"2018","unstructured":"Le Roy\u00a0B, Gelli\u00a0M, Pittau\u00a0G et\u00a0al (2018) Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg 105:839\u2013847","journal-title":"Br J Surg"},{"key":"1660_CR8","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jvir.2021.08.009","volume":"32","author":"A Sarwar","year":"2021","unstructured":"Sarwar\u00a0A, Ali\u00a0A, Ljuboja\u00a0D, Weinstein\u00a0JL et al (2021) Neoadjuvant yttrium-90 transarterial radioembolization with resin microspheres prescribed using the medical internal radiation dose model for intrahepatic cholangiocarcinoma. J\u00a0Vasc Interv Radiol 32:1560\u20131568","journal-title":"J Vasc Interv Radiol"},{"key":"1660_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2019","unstructured":"Edeline\u00a0J, Touchefeu\u00a0Y, Guiu\u00a0B et al (2019) Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 6:51\u201359","journal-title":"JAMA Oncol"},{"key":"1660_CR10","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1007\/s00268-018-4558-1","volume":"42","author":"T Sumiyoshi","year":"2018","unstructured":"Sumiyoshi\u00a0T, Shima\u00a0Y, Okabayashi\u00a0T et\u00a0al (2018) Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma. World J Surg 42:2910\u20132918","journal-title":"World J Surg"},{"key":"1660_CR11","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1245\/s10434-020-08486-7","volume":"27","author":"D Riby","year":"2020","unstructured":"Riby\u00a0D, Mazzotta\u00a0AD, Bergeat\u00a0D et\u00a0al (2020) Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Ann Surg Oncol 27:3729\u20133737","journal-title":"Ann Surg Oncol"},{"key":"1660_CR12","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1245\/s10434-019-07336-5","volume":"26","author":"XF Zhang","year":"2019","unstructured":"Zhang\u00a0XF, Lv\u00a0Y, Weiss\u00a0M et\u00a0al (2019) Should utilization of lymphadenectomy vary according to morphologic subtype of intrahepatic cholangiocarcinoma? Ann Surg Oncol 26:2242\u20132250","journal-title":"Ann Surg Oncol"},{"key":"1660_CR13","first-page":"20210008","volume":"3","author":"LS Kiefer","year":"2021","unstructured":"Kiefer\u00a0LS, Sekler\u00a0J, G\u00fcckel\u00a0B et al (2021) Impact of 18F-FDG-PET\/CT on clinical management in patients with cholangiocellular carcinoma. BJR Open 3:20210008","journal-title":"BJR Open"},{"key":"1660_CR14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jso.24524","volume":"115","author":"S Buettner","year":"2017","unstructured":"Buettner\u00a0S, Koerkamp\u00a0BG, Ejaz\u00a0A et al (2017) The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients\u2014a multi-institutional analysis. J\u00a0Surg Oncol 115:312\u2013318","journal-title":"J Surg Oncol"},{"key":"1660_CR15","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1245\/s10434-020-09478-3","volume":"28","author":"O Utuama","year":"2021","unstructured":"Utuama\u00a0O, Permuth\u00a0JB, Dagne\u00a0G et al (2021) Neoadjuvant chemotherapy for intrahepatic cholangiocarcinoma: a propensity score survival analysis supporting use in patients with high-risk disease. Ann Surg Oncol 28:1939\u20131949","journal-title":"Ann Surg Oncol"},{"key":"1660_CR16","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.amjsurg.2021.02.029","volume":"221","author":"TL Sutton","year":"2021","unstructured":"Sutton\u00a0TL, Billingsley\u00a0KG, Walker\u00a0BS et\u00a0al (2021) Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. Am J Surg 221:1182\u20131187","journal-title":"Am J Surg"},{"key":"1660_CR17","doi-asserted-by":"publisher","first-page":"100354","DOI":"10.1016\/j.ctarc.2021.100354","volume":"27","author":"A Rizzo","year":"2021","unstructured":"Rizzo\u00a0A, Brandi\u00a0G (2021) Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review. Cancer Treat Res Commun 27:100354","journal-title":"Cancer Treat Res Commun"},{"key":"1660_CR18","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ejso.2019.03.023","volume":"45","author":"S Yadav","year":"2019","unstructured":"Yadav\u00a0S, Xie\u00a0H, Bin-Riaz\u00a0I et al (2019) Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched analysis. Eur J Surg Oncol 45:1432\u20131438","journal-title":"Eur J Surg Oncol"},{"key":"1660_CR19","doi-asserted-by":"publisher","first-page":"100417","DOI":"10.1016\/j.jhepr.2021.100417","volume":"4","author":"F Thol","year":"2021","unstructured":"Thol\u00a0F, Gairing\u00a0SJ, Czauderna\u00a0C et\u00a0al (2021) Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. JHEP Rep 4:100417","journal-title":"JHEP Rep"},{"key":"1660_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/jso.24633","volume":"116","author":"BN Reames","year":"2017","unstructured":"Reames\u00a0BN, Ejaz\u00a0A, Koerkamp\u00a0BG et\u00a0al (2017) Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: a\u00a0multiinstitutional analysis. J\u00a0Surg Oncol 116:133\u2013139","journal-title":"J Surg Oncol"},{"key":"1660_CR21","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1245\/s10434-019-07260-8","volume":"26","author":"A Si","year":"2019","unstructured":"Si\u00a0A, Li\u00a0J, Yang\u00a0Z et al (2019) Impact of anatomical versus non-anatomical liver resection on short- and long-term outcomes for patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol 26:1841\u20131850","journal-title":"Ann Surg Oncol"},{"key":"1660_CR22","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1245\/s10434-019-08192-z","volume":"27","author":"J Li","year":"2020","unstructured":"Li\u00a0J, Moustafa\u00a0M, Linecker\u00a0M et al (2020) ALPPS for locally advanced intrahepatic cholangiocarcinoma: did aggressive surgery lead to the oncological benefit? An international multi-center study. Ann Surg Oncol 27:1372\u20131384","journal-title":"Ann Surg Oncol"},{"key":"1660_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.crad.2013.09.009","volume":"69","author":"JM Theysohn","year":"2014","unstructured":"Theysohn\u00a0JM, Ertle\u00a0J, Muller\u00a0S et\u00a0al (2014) Hepatic volume changes after lobar selective internal radiation therapy (SIRT) of hepatocellular carcinoma. Clin Radiol 69:172\u2013178","journal-title":"Clin Radiol"},{"key":"1660_CR24","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1245\/s10434-017-5950-z","volume":"24","author":"F Pardo","year":"2017","unstructured":"Pardo\u00a0F, Sangro\u00a0B, Lee\u00a0RC et al (2017) The post-SIR-spheres surgery study (P4S): retrospective analysis of safety following hepatic resection or transplantation in patients previously treated with selective internal radiation therapy with yttrium-90 resin microspheres. Ann Surg Oncol 24:2465\u20132473","journal-title":"Ann Surg Oncol"},{"key":"1660_CR25","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1245\/s10434-019-07483-9","volume":"26","author":"K Sahara","year":"2019","unstructured":"Sahara\u00a0K, Tsilimigras\u00a0DI, Merath\u00a0K et\u00a0al (2019) Therapeutic index associated with lymphadenectomy among patients with intrahepatic cholangiocarcinoma: which patients benefit the most from nodal evaluation? Ann Surg Oncol 26:2959\u20132968","journal-title":"Ann Surg Oncol"},{"key":"1660_CR26","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1007\/s00268-017-4453-1","volume":"42","author":"F Bagante","year":"2018","unstructured":"Bagante\u00a0F, Spolverato\u00a0G, Weiss\u00a0M et al (2018) Surgical management of intrahepatic cholangiocarcinoma in patients with cirrhosis: impact of lymphadenectomy on peri-operative outcomes. World J Surg 42:2551\u20132560","journal-title":"World J Surg"},{"key":"1660_CR27","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00464-015-4430-4","volume":"30","author":"F Ratti","year":"2016","unstructured":"Ratti\u00a0F, Cipriani\u00a0F, Ariotti\u00a0R et al (2016) Safety and feasibility of laparoscopic liver resection with associated ymphadenectomy for intrahepatic cholangiocarcinoma: a\u00a0propensity score-based case-matched analysis from a\u00a0single institution. Surg Endosc 30:1999\u20132010","journal-title":"Surg Endosc"},{"key":"1660_CR28","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1007\/s00464-016-4817-x","volume":"30","author":"W Lee","year":"2016","unstructured":"Lee\u00a0W, Park\u00a0JH, Kim\u00a0JY et\u00a0al (2016) Comparison of perioperative and oncologic outcomes between open and laparoscopic liver resection for intrahepatic cholangiocarcinoma. Surg Endosc 30:4835\u20134840","journal-title":"Surg Endosc"},{"key":"1660_CR29","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/hep.28744","volume":"64","author":"G Sapisochin","year":"2016","unstructured":"Sapisochin\u00a0G, Facciuto\u00a0M, Rubbia-Brandt\u00a0L et al (2016) Liver transplantation for \u201cvery early\u201d intrahepatic cholangiocarcinoma: International retrospective study supporting a\u00a0prospective assessment. Hepatology 64:1178\u20131188","journal-title":"Hepatology"},{"key":"1660_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16906","author":"RR McMillan","year":"2021","unstructured":"McMillan\u00a0RR, Javle\u00a0M, Kodali\u00a0S et al (2021) Survival following liver transplantation for locally-advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transplant. https:\/\/doi.org\/10.1111\/ajt.16906","journal-title":"Am J Transplant"},{"key":"1660_CR31","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose\u00a0JN, Fox\u00a0RP, Palmer\u00a0DH et\u00a0al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a\u00a0randomised, controlled, multicentre, phase 3\u00a0study. Lancet Oncol 20:663\u2013673","journal-title":"Lancet Oncol"},{"key":"1660_CR32","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline\u00a0J, Benabdelghani\u00a0M, Bertaut\u00a0A et al (2019) Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a\u00a0randomized phase III study. J\u00a0Clin Oncol 37:658\u2013667","journal-title":"J Clin Oncol"},{"key":"1660_CR33","doi-asserted-by":"publisher","first-page":"e14013","DOI":"10.1097\/MD.0000000000014013","volume":"98","author":"KW Ma","year":"2019","unstructured":"Ma\u00a0KW, Cheung\u00a0TT, Leung\u00a0B et al (2019) Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: a\u00a0meta-analysis. Medicine 98:e14013","journal-title":"Medicine"},{"issue":"5","key":"1660_CR34","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1245\/s10434-016-5560-1","volume":"23","author":"AY Hammad","year":"2016","unstructured":"Hammad\u00a0AY, Berger\u00a0NG, Eastwood\u00a0D et\u00a0al (2016) Is radiotherapy warranted following intrahepatic cholangiocarcinoma resection? The impact of surgical margins and lymph node status on survival. Ann Surg Oncol 23(5):912\u2013920","journal-title":"Ann Surg Oncol"},{"key":"1660_CR35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.radonc.2018.05.011","volume":"128","author":"YK Lin","year":"2018","unstructured":"Lin\u00a0YK, Hsieh\u00a0MC, Wang\u00a0WW et\u00a0al (2018) Outcomes of adjuvant treatments for resectable intrahepatic cholangiocarcinoma: chemotherapy alone, sequential chemoradiotherapy, or concurrent chemoradiotherapy. Radiother Oncol 128:575\u2013583","journal-title":"Radiother Oncol"},{"key":"1660_CR36","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1007\/s11605-018-3861-3","volume":"22","author":"R Ramanathan","year":"2018","unstructured":"Ramanathan\u00a0R, Borrebach\u00a0J, Tohme\u00a0S, Tsung\u00a0A (2018) Preoperative biliary drainage is associated with increased complications after liver resection for proximal cholangiocarcinoma. J\u00a0Gastrointest Surg 22:1950\u20131957","journal-title":"J Gastrointest Surg"},{"key":"1660_CR37","doi-asserted-by":"publisher","first-page":"108897","DOI":"10.1016\/j.ejrad.2020.108897","volume":"125","author":"A Mehrabi","year":"2020","unstructured":"Mehrabi\u00a0A, Khajeh\u00a0E, Ghamarnejad\u00a0O et al (2020) Meta-analysis of the efficacy of preoperative biliary drainage in patients undergoing liver resection for perihilar cholangiocarcinoma. Eur J Radiol 125:108897","journal-title":"Eur J Radiol"},{"key":"1660_CR38","first-page":"S0039","volume":"20","author":"F Giuliante","year":"2021","unstructured":"Giuliante\u00a0F, Ardito\u00a0F, Aldrighetti\u00a0L et\u00a0al (2021) Liver resection for perihilar cholangiocarcinoma: Impact of biliary drainage failure on postoperative outcome. Results of an Italian multicenter study. Surgery 20:S39","journal-title":"Surgery"},{"key":"1660_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jamcollsurg.2016.01.060","volume":"223","author":"D Ribero","year":"2016","unstructured":"Ribero\u00a0D, Zimmitti\u00a0G, Aloia\u00a0TA et\u00a0al (2016) Preoperative cholangitis and future liver remnant volume determine the risk of liver failure in patients undergoing resection for hilar cholangiocarcinoma. J\u00a0Am Coll Surg 223:87\u201397","journal-title":"J Am Coll Surg"},{"key":"1660_CR40","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S2468-1253(18)30234-6","volume":"3","author":"RJS Coelen","year":"2018","unstructured":"Coelen\u00a0RJS, Roos\u00a0E, Wiggers\u00a0JK et\u00a0al (2018) Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a\u00a0multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol 3:681\u2013690","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1660_CR41","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.surg.2016.08.008","volume":"161","author":"K Komaya","year":"2021","unstructured":"Komaya\u00a0K, Ebata\u00a0T, Yokoyama\u00a0Y et\u00a0al (2021) Verification of the oncologic inferiority of percutaneous biliary drainage to endoscopic drainage: a propensity score matching analysis of resectable perihilar cholangiocarcinoma. Surgery 161:394\u2013404","journal-title":"Surgery"},{"key":"1660_CR42","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1245\/s10434-020-08258-3","volume":"27","author":"PB Olthof","year":"2020","unstructured":"Olthof\u00a0PB, Aldrighetti\u00a0L, Alikhanov\u00a0R, Perihilar Cholangiocarcinoma Collaboration Group et al (2020) Portal vein embolization is associated with reduced liver failure and mortality in high-risk resections for perihilar cholangiocarcinoma. Ann Surg Oncol 27:2311\u20132318","journal-title":"Ann Surg Oncol"},{"key":"1660_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000335718","volume":"29","author":"T Ebata","year":"2012","unstructured":"Ebata\u00a0T, Yokoyama\u00a0Y, Igami\u00a0T et\u00a0al (2012) Portal vein embolization before extended hepatectomy for biliary cancer: current technique and review of 494 consecutive embolizations. Dig Surg 29:23\u201329","journal-title":"Dig Surg"},{"key":"1660_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.hpb.2016.10.008","volume":"19","author":"PB Olthof","year":"2017","unstructured":"Olthof\u00a0PB, Coelen\u00a0RJS, Wiggers\u00a0JK et al (2017) High mortality after ALPPS for perihilar cholangiocarcinoma: case-control analysis including the first series from the international ALPPS registry. HPB 19:381\u2013387","journal-title":"HPB"},{"key":"1660_CR45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.hbpd.2020.02.007","volume":"19","author":"M Baltatzis","year":"2020","unstructured":"Baltatzis\u00a0M, Jegatheeswaran\u00a0S, Siriwardena\u00a0AK (2020) Neoadjuvant chemoradiotherapy before resection of perihilar cholangiocarcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 19:103\u2013108","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"1660_CR46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12885-020-06895-1","volume":"20","author":"N Kuriyama","year":"2020","unstructured":"Kuriyama\u00a0N, Usui\u00a0M, Gyoten\u00a0K et al (2020) Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status. BMC Cancer 20:405","journal-title":"BMC Cancer"},{"key":"1660_CR47","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","volume":"143","author":"S Darwish Murad","year":"2012","unstructured":"Darwish Murad\u00a0S, Kim\u00a0WR, Harnois\u00a0D et\u00a0al (2012) Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 143:88\u201398","journal-title":"Gastroenterology"},{"key":"1660_CR48","doi-asserted-by":"publisher","first-page":"e0156127","DOI":"10.1371\/journal.pone.0156127","volume":"11","author":"HT Mantel","year":"2016","unstructured":"Mantel\u00a0HT, Westerkamp\u00a0AC, Adam\u00a0R et\u00a0al (2016) European liver and intestine transplant association (ELITA). Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival. PLoS ONE 11:e156127","journal-title":"PLoS ONE"},{"issue":"2","key":"1660_CR49","first-page":"16","volume":"34","author":"M Schmelzle","year":"2021","unstructured":"Schmelzle\u00a0M, Benzing\u00a0C, Fischer\u00a0L et al (2021) Feasibility and efficacy of adjuvant chemotherapy with gemcitabine after liver transplantation for locally unresectable perihilar cholangiocarcinoma\u2014a multi-center, randomized, controlled trial (pro-duct 001). Transpl Int 34(2):16","journal-title":"Transpl Int"},{"key":"1660_CR50","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.3390\/cancers13153657","volume":"13","author":"A Lauterio","year":"2021","unstructured":"Lauterio\u00a0A, De Carlis\u00a0R, Centonze\u00a0L et al (2021) Current surgical management of peri-hilar and intra-hepatic cholangiocarcinoma. Cancers (Basel) 13:3657","journal-title":"Cancers (Basel)"},{"key":"1660_CR51","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1245\/s10434-017-6095-9","volume":"24","author":"BL Ecker","year":"2017","unstructured":"Ecker\u00a0BL, Vining\u00a0CC, Roses\u00a0R et al (2017) Identification of patients for adjuvant therapy after resection of carcinoma of the extrahepatic bile ducts: a propensity score-matched analysis. Ann Surg Oncol 24:3926\u20133933","journal-title":"Ann Surg Oncol"},{"key":"1660_CR52","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.18.02178","volume":"37","author":"RT Shroff","year":"2019","unstructured":"Shroff\u00a0RT, Kennedy\u00a0EB, Bachini\u00a0M et\u00a0al (2019) Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J\u00a0Clin Oncol 37:1015\u20131027","journal-title":"J Clin Oncol"}],"container-title":["Die Chirurgie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-022-01660-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-022-01660-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-022-01660-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T09:04:33Z","timestamp":1656579873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-022-01660-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1660"],"URL":"https:\/\/doi.org\/10.1007\/s00104-022-01660-5","relation":{},"ISSN":["2731-6971","2731-698X"],"issn-type":[{"value":"2731-6971","type":"print"},{"value":"2731-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"9 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.\u00a0Seehofer gibt den Erhalt von Honoraren oder Beratungshonoraren von BTG, Johnson & Johnson, Gubert, Novartis, Olympus und SIRTEX an sowie die Teilnahme an einem von den folgenden Unternehmen gesponserten speaker\u2019s bureau: Abbvie, Astellas, Bayer, BTG, Eisai, Johnson & Johnson, MSD\/Merck, Novartis, Olympus. T.\u00a0Berg gibt Zusch\u00fcsse und Forschungsf\u00f6rderung von Abbvie, BMS, Gilead, MSD\/Merck, Humedics, Intercept, Merz, Novartis und Sequana Medical an sowie den Erhalt von Honoraren oder Beratungshonoraren von Abbvie, Alexion, Bayer, Gilead, Eisai, Humedics, Intercept, Ipsen, Janssen, MSD\/Merck, Novartis, Roche, Sequana Medical, SIRTEX, SOBI und Shionogi, des Weiteren die Teilnahme an einem von den folgenden Unternehmen gesponserten speaker\u2019s bureau: Abbvie, Alexion, Bayer, Gilead, Eisai, Intercept, Ipsen, Janssen, MedUpdate GmbH, MSD\/Merck, Novartis, Sequana Medical und SIRTEX. S.\u00a0Rademacher und T.\u00a0Denecke geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}